Latest Share Chat

AMYT.L Share News (AMYT)

AMYT.L Information

There is currently no data for AMYT

Amryt Pharma reaches agreement with French authorities over Lojuxta

Wed, 17th Oct 2018 11:31

(Sharecast News) - Orphan drug company Amryt Pharma has reached agreement with France's Comité économique des produits de santé (CEPS) to reimburse 'Lojuxta' (lomitapide) for the treatment of adult patients with homozygous familial hypercholesterolaemia (HoFH) in France.The AIM-traded firm said that, from the first quarter of 2019, adult HoFH patients suffering with the ultra-rare, life-threatening genetic condition could receive a 'first in class' medicine to reduce low density lipoprotein (LDL) cholesterol, often referred to as 'bad cholesterol', when used as an adjunctive therapy to other lipid lowering medications and where available, apheresis.It said the clinical value of Lojuxta in managing adult HoFH had been demonstrated in clinical trials and in the real world.The approval now meant that Lojuxta was available across all five of the EU's major markets - France, the UK, Italy, Germany and Spain - either by responding to named patient requests or on a fully reimbursed basis and is in line with Amryt's strategy to make Lojuxta available to more patients across Amryt's licensed territories."A clear aim in continuing the positive momentum in Lojuxta revenues is to ensure reimbursement in our core territories," said Amryt chief executive officer Joe Wiley."Following closely on from our recent approval with the NHS in England, where we have already started treating patients, we are now very pleased to be able to make Lojuxta available to adult HoFH patients in France."

More News

8 May 2018 13:13

Former Amryt Pharma Non-Executive Friel Sells 8.4 Million Shares (ALLISS)

LONDON (Alliance News) - Amryt Pharma PLC on Tuesday said on Tuesday a company owned by a former non-executive director has sold 8.4 million shares in the company.Raglan Road Capital Ltd is

15 Mar 2018 14:15

Amryt 2017 Revenue Soars On Lojuxta Sales As New In-Licence Sealed

LONDON (Alliance News) - Amryt Pharma PLC said Thursday it has signed an in-licence agreement for a gene therapy platform, with the company making a "very start in for to

15 Mar 2018 05:25

UK Stocks-Factors to watch on March 15

March 15 (Reuters) - Britain's FTSE 100 index is seen opening 2 points higher at 7,135 on Thursday, according to financial bookmakers. * SHELL: Royal Dutch Shell is close to

8 Mar 2018 15:39

UK Earnings, Trading Statements Calendar - Next 7 Days

Friday 9 March SIGFull Year ResultsInmarsatFull Year ResultsGVC Year 12

6 Feb 2017 09:23

Amryt Pharma Gets Positive Study Results For Possible Acromegaly Drug

2 Dec 2016 08:07

Amryt Pharma secures €20m loan from European Investment Bank

(ShareCast News) - AIM-listed Amryt Pharma has secured a €20m loan from the European Investment Bank to secure its near and mid-term funding for its gel product and a development for a drug compound compound. The loan secures funding for its product Episalvan, which treats skin disorder Epidermolysi

7 Nov 2016 12:19

Amryt Pharma's drug compound gains FDA approval

(ShareCast News) - The US Food and Drug Administration (FDA) has granted orphan drug designation to AIM-listed Amryt Pharma's drug compound which has the potential to treat acromegaly. The drug compound, AP102, now qualifies for tax credits for qualified clinical trials and market exclusivity on reg

13 Sep 2016 16:10

Amryt Pharma positive about drug developments

(ShareCast News) - Clinical stage specialty pharma company focused on best in class treatments for orphan diseases, Amryt Pharma, posted its interim financial statements for the six months to 30 June on Tuesday. The AIM-traded firm was admitted to trading on AIM and the ESM market of the Irish Stock

9 Jun 2016 09:55

Amryt Pharma Plans Trials Of Episalvan Product By End Of 2016

19 Apr 2016 12:05

Amryt Pharma reverses onto AIM to advance orphan drug strategy

(ShareCast News) - Speciality drug developer Amryt Pharma has completed its flotation via the reverse takeover of AIM-listed Fastnet, raising £10m of new cash in the process and acquiring two operating companies. As part of the float, Amryt acquired drug German drug development and manufacturing com

19 Apr 2016 08:52

Latest Share Chat

AMYT.L Share News (AMYT)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Amryt Pharma reaches agreement with French authorities over Lojuxta

Login to your account

Quickpicks are a member only feature

Login to your account